Kristine Wiborg Høgsbjerg

Kristine Wiborg Høgsbjerg

Auto-generated profile, based on publicly available information

Kristine Wiborg Høgsbjerg

Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2024 in Radiotherapy and Oncology
Verified
Journal Article
Open access
KHKristine W. Høgsbjerg
Kristine W. Høgsbjerg
EMElse Maae
Else Maae
MNMette H. Nielsen
Mette H. Nielsen
LSLars Stenbygaard
Lars Stenbygaard
APAnders N. Pedersen
Anders N. Pedersen
BOBirgitte V. Offersen
Birgitte V. Offersen
Partial breast irradiation (PBI)has beenthe Danish Breast Cancer Group(DBCG) standard for selected breast cancer patients since 2016 based onearlyresults from the DBCG PBI trial.During trial accrual, respiratory-gated radiotherapy was introduced in Denmark. This study aims to investigate the effect of respiratory-gating on mean heart dose (MHD). From 2009 to 2016 the DBCG PBI trial included 230 patientswith left-sided breast cancer receiving external beam PBI, 40 Gy/15 fractions/3 weeks.Localization of the tumor bed on the planning CT scan, the use of respiratory-gating, coverage of the clinical target volume (CTV), and doses to organs at risk were collected. Respiratory-gating was used in 123 patients (53 %). In 176 patients (77 %) the tumor bed was in the upper and in 54 patients (23 %) in the lower breast quadrants. The median MHD was 0.37 Gy (interquartile range 0.26-0.57 Gy), 0.33 Gy (0.23-0.49 Gy) for respiratory-gating, and 0.49 Gy (0.31-0.70 Gy) for free breathing, p < 0.0001. MHD was < 1 Gy in 206 patients (90 %) and < 2 Gy in 221 patients (96 %). Respiratory-gating led to significantly lower MHD for upper-located, but not for lower-located tumor beds, however, all MHD were low irrespective of respiratory-gating. Respiratory-gating did not improve CTV coverage or lower lung doses. PBI ensured a low MHD for most patients. Adding respiratory-gating further reduced MHD for upper-located but not for lower-located tumor beds but did not influence target coverage or lung doses. Respiratory-gating is no longer DBCG standard for left-sided PBI.

20 August 2026 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BOBirgitte V. Offersen
Birgitte V. Offersen
JAJan Alsner
Jan Alsner
KHKristine Høgsbjerg
Kristine Høgsbjerg
HNHanne M. Nielsen
Hanne M. Nielsen
EMElse Maae
Else Maae
OCon behalf of the DBCG RT Committee
on behalf of the DBCG RT Committee
PURPOSE: Adjuvant radiotherapy for node-positive breast cancer (BC) using 50Gy/25fx has been Danish Breast Cancer Group (DBCG) standard. Hypofractionated radiotherapy based on 40Gy/15fx has been increasingly used; however, it is less frequently for locoregional therapy because of concern over more morbidity. DBCG Skagen trial 1 hypothesized that 40Gy/15fx did not cause more lymphedema than 50Gy/25fx 3 years after radiotherapy without compromising the pattern of failure. METHODS: Skagen trial 1 is a phase III, noninferiority trial randomly assigning high-risk BC patients with an indication for locoregional radiotherapy to standard 50Gy/25fx versus experimental 40Gy/15fx. The primary end point was arm lymphedema; assuming a 3-year incidence with 50Gy/25fx of 10%, noninferiority was predefined to maximum 5% excess incidence with 40Gy/15fx. Accrual continued until 3-year estimates were reported in 1,012 patients. RESULTS: Between 2015 and 2021, 2,963 patients consented from 17 centers; the intention-to-treat cohort comprised 2,908 patients: 1,444 had 50Gy (50%), and 1,464 had 40Gy (50%). The median age was 57 years (range, 23-86). At a median follow-up of 4.1 years (IQR, 3.0-5.0), the 3-year rates of lymphedema were 9.4% (50Gy) versus 8.0% (40Gy), odds ratio 0.84 (95% CI, 0.62 to 1.14), and P = .27, thus within the +5-percentage-point noninferiority margin. The median follow-up for cancer outcomes was 5.25 years (IQR, 4.26 to 6.96). Within 8 years, the hazard ratio for locoregional recurrence was 0.96 (95% CI, 0.62 to 1.51), that for distant recurrence was 1.10 (95% CI, 0.89 to 1.37), that for BC mortality was 1.25 (95% CI, 0.93 to 1.66), and that for all-cause mortality was 1.08 (95% CI, 0.85 to 1.36), thus all with no differences by random assignment. CONCLUSION: 40Gy/15fx for locoregional radiotherapy of BC did not result in more lymphedema compared with 50Gy/25fx. There were no differences in locoregional or distant recurrences, breast cancer mortality, nor all-cause mortality between the random assignment arms.

14 May 2026 in Radiotherapy and Oncology
Verified
Journal Article
Open access
KHKristine Wiborg Høgsbjerg
Kristine Wiborg Høgsbjerg
MTMette Skovhus Thomsen
Mette Skovhus Thomsen
EMElse Maae
Else Maae
IMIngvil Mjaaland
Ingvil Mjaaland
MNMette Holck Nielsen
Mette Holck Nielsen
BOBirgitte Vrou Offersen
Birgitte Vrou Offersen
Adjuvant loco-regional radiotherapy reduces recurrence risk and enhances survival in early-stage breast cancer. The ESTRO consensus guideline on target volume delineation for elective radiotherapy of early-stage breast cancer, published in 2015, sought to standardise contouring practices. In the DBCG Skagen Trial 1, all clinical target volume (CTV) delineations followed the ESTRO guideline, allowing pre-planned prospective validation. This study aimed to characterise the loco-regional recurrence pattern in accordance with target delineation as per the ESTRO guideline. DBCG Skagen Trial 1 enrolled 2,963 patients (2,908 in the intention-to-treat cohort). Loco-regional recurrences (LRR), with or without concurrent distant recurrence, were identified from imaging and medical records, and categorised as inside the CTV, marginal miss, or distant recurrence relative to the ESTRO-defined CTVs. At median follow-up of 5.2 years (IQR 4.1-6.7), 78 patients developed LRR: 41 isolated LRR and 37 with concurrent distant recurrence. Among the 78 patients with LRR, 74 (95%) had recurrences located within the ESTRO-defined CTVs and were planned to receive the full prescribed dose. All local recurrences were within the CTVp, and all but three regional recurrences were within the CTVn. Only three marginal misses were identified. Loco-regional recurrences in the DBCG Skagen Trial 1 occurred almost exclusively within the ESTRO-defined CTVs, providing prospective validation of the guideline, without evidence suggesting a need for modification of target volumes.

27 September 2025 in The Breast
Verified
Journal Article
Open access
KHKristine Wiborg Høgsbjerg
Kristine Wiborg Høgsbjerg
EMElse Maae
Else Maae
MNMette Holck Nielsen
Mette Holck Nielsen
MMMarie Louise Holm Milo
Marie Louise Holm Milo
MMMaja Vestmø Maraldo
Maja Vestmø Maraldo
BOBirgitte Vrou Offersen
Birgitte Vrou Offersen
Following breast-conserving surgery (BCS), patients with narrow surgical margins frequently undergo repeat surgery (RS) or receive a tumour-bed boost to reduce the risk of local recurrence. Both interventions may increase the risk of late toxicity, including breast induration and adverse cosmetic outcomes. Comparative long-term data on these outcomes remain limited. This post hoc analysis assessed the impact of RS and tumour-bed boost on grade 2-3 breast induration and cosmetic outcomes in patients receiving whole-breast irradiation (WBI) for early-stage breast cancer or ductal carcinoma in situ (DCIS). The analysis included 1919 patients from two multicentre randomised phase III trials within the Danish Breast Cancer Group (DBCG): DBCG HYPO (WBI 50Gy/25fr versus 40Gy/15fr) and DBCG PBI (40Gy/15fr, WBI versus partial breast irradiation (PBI)). Of these, 303 patients (16 %) underwent RS and 220 patients (11 %) received a boost. Patients were categorised into four groups: 'RS and boost', 'boost only', 'RS only', and 'No RS, no boost'. At 5 years, the cumulative incidence of grade 2-3 breast induration was highest in the 'RS and boost' group (30.7 %), followed by 'boost only' (25.7 %), 'RS only' (18.1 %), and 'No RS, no boost' (13.5 %). Adjusted hazard ratios confirmed this pattern. No significant differences in cosmetic outcomes were observed between the 'RS only' and 'boost only' groups at 3 or 5 years. A tumour-bed boost was associated with a higher risk of breast induration compared to RS, with no difference in cosmetic outcome.


15 September 2025 in Technical Innovations & Patient Support in Radiation Oncology
Verified
Journal Article
Open access
KHKristine W. Høgsbjerg
Kristine W. Høgsbjerg
AKAnne W. Kristensen
Anne W. Kristensen
MMMette Møller
Mette Møller
EMElse Maae
Else Maae
MMMaja V. Maraldo
Maja V. Maraldo
BOBirgitte V. Offersen
Birgitte V. Offersen
Participation in clinical trials is essential to advancing oncological treatments, yet equitable trial access remains challenging. Diverse patient inclusion strengthens external validity and enhances the generalisability of trial outcomes. However, barriers to trial participation persist, and the factors influencing patient enrolment are not fully understood. This study investigates the patient perspective on participation in the Danish Breast Cancer Group (DBCG) Proton Trial. Patients eligible for the DBCG Proton Trial were invited to participate in interviews. Patients were selected to ensure geographical and perspective-based diversity, including randomised and non-randomised patients from eight radiotherapy clinics in Denmark. Semi-structured interviews were conducted via telephone, transcribed, and analysed using an inductive approach to identify the patient perspective on trial participation. A total of fifteen patients were interviewed. The analysis identified five themes encompassing patients’ motivators and barriers to trial participation: distance to the treatment facility, timing of trial information, decisional support, clinical equipoise and patient needs. These factors were reported by both randomised and non-randomised patients. Participation in the DBCG Proton Trial was determined by both logistical and personal factors. Distance to the proton treatment facility was the most important barrier, while the potential for reduced late effects was the main motivator. The decision was difficult for most patients, often guided by one dominant concern rather than a balanced consideration of multiple factors. These findings suggest that improved trial communication, decisional support, and attention to geographical barriers are essential for promoting equitable participation in clinical trials.